

Adherium progress update on US pilots with key partners

Highlights:

- **“Hailie® platform is extremely easy to use, and the data is highly valuable to us.”**
- **“...they are user-friendly, fit a broad range of inhalers, are efficient, and accurate. As a result, our patients and research team have loved using them.”**
- **“Hailie® digital sensors are a crucial component of our studies and will be a part of all our future Asthma studies.”**
- **“Our partnership with Adherium enables us to achieve our mission of advancing the quality of life for patients suffering from pulmonary disease,”**

Melbourne, Australia – 1 September 2021: Adherium Limited (ASX: ADR), a leader in digital inhaled device adherence, remote patient monitoring and data management solutions, is pleased to announce a progress update and positive endorsements with its business partner Monaghan Medical Corporation, a wholly owned subsidiary of Trudell Medical Limited, and National Jewish Health, a leading US respiratory hospital based in Denver, Colorado. The Hailie® platform and sensors are being used in two Asthma clinical mobile health studies at National Jewish Health.

Dr Brian D. Modena, MD, MSc (Co-Investigator), and Dr Eileen Wang, MD, MPH (Principal Investigator) are leading the Creation of Home-based Asthma Real-World Measures with Mobile Health (CHARM) study and the Measuring Omalizumab Responses using Real-world Evidence (MORRE) study. Both studies are using real world evidence with data collected at home, using several mobile and digital health technologies. The studies are designed to assess the efficacy, health benefits, and side effects of Asthma monoclonal therapies used in the treatment of moderate to severe Asthma patients.

Mr Rick Legleiter, Adherium’s Chief Executive Officer, outlines, “The study of biologics are a strategic fit with our business plan focusing on the expensive and difficult to treat patients that are stressing the economic models of healthcare systems around the world. In this context, understanding and addressing therapeutic and compliance issues are an important value-added benefit that healthcare systems realize from our product portfolio.”

Dr Modena expressed how the Adherium product is contributing to his clinical study, “The Hailie® digital sensors are a crucial component of our studies and will be a part of all our future



Asthma studies. In particular, we use them in the assessment of both adherence to maintenance inhaler medications and the use of rescue medications. In past studies, and currently in clinical practice, adherence and medication use data was collected only by patient recall, which tends to be inaccurate. The Hailie® platform is extremely easy to use, and the data is highly valuable to us.”

The successful launch and adoption of the Hailie® sensors, phone application and platform at clinical sites and leading institutions such as National Jewish in the US puts Adherium in a valuable position to leverage its technology beyond clinical trials and into broader commercial use. Gaining first-hand patient and provider usability experience with the Hailie® sensors, Hailie® apps, and digital platform is essential for the product’s broader commercialization into additional market segments. Ease of use is critical for advanced digital health technologies to be adopted and used in the marketplace.

Dr Wang added, “The Hailie® platform and devices smartly address two pivotal areas in which we still struggle both clinically and in research: controller medication adherence and rescue inhaler use. Importantly, they are user-friendly, fit a broad range of inhalers, are efficient, and accurate. As a result, our patients and research team have loved using them.”

Advancing further and adding to adherence, the next generation of Hailie® sensors with physiological measures are in development with submission for regulatory review in the US and other jurisdictions through this calendar year and into 2022. As regulatory clearances are received, our sensors will be deployed into commercial pilots shortly thereafter to improve patient adherence, remote monitoring and ultimately to reduce hospitalizations for the 6.9 million severe uncontrolled and difficult to treat Asthma and Chronic Obstructive Pulmonary Disease (COPD) patients such as the Asthma patients being studied at National Jewish. This patient group is estimated to represent a total addressable market of US\$1.5 billion.

“Our partnership with Adherium enables us to achieve our mission of advancing the quality of life for patients suffering from pulmonary disease,” states Gerald Slemko, CEO of Trudell Medical Limited and President of Monaghan Medical Corporation. “Our focus is on providing our clinical partners with well researched and clinically validated innovative products and technology. Following delays in the past year caused by COVID-19 access challenges at hospitals and with providers, we are reinvigorating our clinical and commercial pilot programs in the US. We continue to build the Monaghan brand and further establish our position as market leaders in helping people breathe better.”

About Adherium (ASX: ADR)

Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The Company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium's Hailie® solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when it is time to take doses, and by providing access to usage history to better understand patterns in their asthma and COPD.

These tools ultimately enable patients, with their physicians, to more effectively manage their Asthma and COPD and at the same time potentially deliver significant healthcare cost savings to payors and providers. Learn more at www.adherium.com

About National Jewish Health

National Jewish Health is the leading respiratory hospital in the United States. Founded 122 years ago as a non-profit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to ground-breaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit <https://www.nationaljewish.org/about/news/media-resources>

About Monaghan Medical Corporation

Monaghan, which is based in Plattsburgh, NY, is a US market leader in the manufacturing and sales of respiratory devices, including the Aerochamber® brand of valved holding chambers used with metered dose inhalers, which optimises the delivery of inhaled medication to the lungs, the Aerobika® brand of oscillating positive expiratory pressure (OPEP) device that has been designed to address the structural and functional challenges in the airways of patients with COPD and the Aero Eclipse® brand of breath actuated nebulizers. Monaghan is a wholly owned subsidiary of Trudell Medical Limited, a 13% shareholder in Adherium. Trudell traces its roots back to 1922. Today, many of Trudell's operating subsidiaries operate on a global basis, collectively doing business in over 100 countries around the world. All Trudell companies are focused on understanding the unmet needs of patients and delivering solutions that improve their quality of life. Learn more at www.monaghanmed.com and www.trudellmedicalgroup.com



This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: Rick Legleiter
CEO
Adherium Limited
investors@adherium.com